The Allergen BioCube (ABC)
A clinician is inside the chamber to monitor subjects' reactions using objective assessments
Subject Sensitivity Matching
Allergen levels are tailored to suit subjects’ sensitivities, thus representing real world conditions
Homogenization of Allergens
Full homogenization throughout subject positions in the chamber, with capabilities to deliver multiple allergens
Allergen BioCube Results
Our Nasal Inflammation Scale (NIS) provides truly quantifiable measurements
The number of FDA approvals that Ora has helped its allergy clients earn over the past 30 years.Learn more about our track record.>>
The Allergen BioCube (ABC) was developed to optimize the aeroallergen distribution process, provide a uniform allergen exposure environment for each study subject, enhance the degree of allergic rhinitis signs and symptoms experienced by subjects, and quantify clinical changes in a consistent and straightforward manner.
This clinical model has been carefully constructed toward two specific goals: 1) to effectively and reproducibly elicit allergic rhinitis signs and symptoms in a well-defined patient population, and 2) to capture clinical effects of test therapies in a controlled manner using both objective and subjective measurements.
The ABC is smaller than all other allergen chambers—at a maximum it hosts 6 study subjects and one staff member. Its design allows for long- or short-exposure periods of diverse allergens including ragweed pollen and dust mite antigens. The ABC’s small size also offers control over chamber air temperature and humidity, as these environmental variables can influence the distribution of allergens within the chamber.